【Health News】 SCL Healthcare Co., Ltd. (hereinafter referred to as SCL Healthcare) participated in the recently held ‘2023 KoNECT-MOHW-MFDS International Conference (hereinafter referred to as KIC)’ and explored the future development direction of the bio industry, including the clinical trial field.
KIC, which marks its 9th anniversary this year, was jointly held by the National Clinical Trial Support Foundation, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety from October 10th to 12th, and was attended by domestic and foreign bio experts, pharmaceutical company developers, clinical researchers, and clinical trial contract organizations. About 1,500 new drug development experts from about 450 companies and institutions, including officials, attended.
At this conference, which lasted for three days, a total of 90 topics, including 8 keynote lectures and 22 sessions, were discussed, various challenges facing the domestic and foreign bio industry were discussed, and new directions for a leap forward were presented. On the 12th, in the ‘Clinical Trials of IVD’ session, Baek Se-yeon, head of SCL Healthcare’s New Drug Development Support Center, participated as moderator and shared actual clinical cases and experiences, including regulations on IVD (in vitro diagnostic device) clinical trials, drawing great interest from participants. got it
In particular, SCL Healthcare operates an exhibition booth at Asia’s largest international conference to introduce SCL Healthcare Central Laboratory (C-LAB), a central laboratory for new drug development clinical trials at an international level, and to provide information on domestic clinical trials in the field. The status and status were widely publicized.
SCL Healthcare C-LAB, established in 2006, is Korea’s first analytical contract research organization (CRO) and has experience in over 600 new drug approval clinical trial tasks, various sample analysis, and biomarker validation. In 2019, it was the first Central Lab in Korea to be designated as a clinical trial sample analysis agency by the Ministry of Food and Drug Safety, and was recognized for the excellence and reliability of its analysis services by obtaining recognition for the international standard ‘ISO 15189’ in the medical testing field for two consecutive times last year.
SCL Healthcare Chairman Lee Kyeong-ryul said, “In the rapidly changing pharmaceutical and bio industry environment, new drug development not only contributes to improving human health, but is also rapidly emerging as a major national business, and efforts to develop innovative new drugs are continuing around the world.” “Care will continue to contribute to the development of clinical trials and research at home and abroad through continuous improvement of research technology,” he said.
Please note that posts that are not related to the content of the article or that defame others, such as using profanity, may be deleted without notice by the administrator.
2023-10-13 01:52:00
#Health #Welfare #News #SCL #Healthcare #participates #Asias #largest #KoNECT #International #Conference
